Ceftazidime plus amikacin plus teicoplanin or vancomycin in the empirical antibiotic therapy in febrile neutropenic cancer patients.

Machine translation Machine translation
类别 Primary study
期刊Oncology reports
Year 1998
連結 Pubmed, DOI
一项前瞻性随机试验进行比较替考拉宁对万古霉素作为经验性癌症患者发热的中性粒细胞抗生素治疗的一部分。 50名病人随机接受头孢他啶（100毫克/公斤每日每8小时），阿米卡星（15毫克/公斤每日每8 h）和替考拉宁（6毫克/公斤，每天一次）和53例接受头孢他啶，阿米卡星（相同剂量）和万古霉素（30毫克/公斤/天，每6小时）。在评估的99集，成功率分别为54％的病人接受万古霉素替考拉宁接受患者和52％（P值0.76，95％的CI - 18 - 23）。的回应率分别为原因不明的发热和感染的患者有类似的记载。有肾毒性或两组之间无显着差异皮肤副作用。总的死亡率为18.9％，其中每组10人死亡。最重要的因素是与死亡相关的真菌感染有关（P = 0.001诊断）。替考拉宁似乎耐受性好，如在经验中中性粒细胞减少癌症病人发烧万古霉素的抗生素治疗有效。
This translation has been produced by an automated software. If you wish to submit your own translation, please send it to translations@epistemonikos.org
Epistemonikos ID: 98410410c67892535d7b0cdb6d516f355a7426f0
First added on: Jun 08, 2011
Warning
This is a machine translation from an article in Epistemonikos.

Machine translations cannot be considered reliable in order to make health decisions.

See an official translation in the following languages: English

If you prefer to see the machine translation we assume you accept our terms of use